Ceftolozane-tazobactam is named as an intervention in 2 current clinical trials in our China, Spain, Turkey, Singapore, Australia and Brazil registers. 2 are recruiting patients now. All registered phases are Phase 4. The sponsor with the most trials is National University of Singapore (1). The most-studied condition is Bloodstream Infection.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
NCT06342115 · ClinicalTrials.gov ↗ · Febrile Neutropenia
|
Phase 4 | Recruiting | Beneficência Portuguesa de São Paulo | Brazil |
|
Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT07004049 · ClinicalTrials.gov ↗ · Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia
|
Phase 4 | Recruiting | National University of Singapore | China, Spain, Turkey, Singapore, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| National University of Singapore | 1 |
| Beneficência Portuguesa de São Paulo | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Turkey | 1 | 1 |
| Clinical trials in Singapore | 1 | 1 |
| Clinical trials in Australia | 1 | 1 |
| Clinical trials in Brazil | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China, Spain, Turkey, Singapore, Australia and Brazil registers name Ceftolozane-tazobactam as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in China, 1 with sites in Spain, 1 with sites in Turkey, 1 with sites in Singapore, 1 with sites in Australia and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
National University of Singapore (1) and Beneficência Portuguesa de São Paulo (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ceftolozane-tazobactam works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ceftolozane-tazobactam works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ceftolozane-tazobactam (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.